These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16644235)

  • 1. Anti-ischaemic effect of ivabradine.
    Ferrari R; Cargnoni A; Ceconi C
    Pharmacol Res; 2006 May; 53(5):435-9. PubMed ID: 16644235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
    Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
    Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
    Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate reduction by pharmacological If current inhibition.
    Cargnoni A; Ceconi C; Stavroula G; Ferrari R
    Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart.
    Ceconi C; Cargnoni A; Francolini G; Parinello G; Ferrari R
    Cardiovasc Res; 2009 Oct; 84(1):72-82. PubMed ID: 19477966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
    Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I f inhibition with ivabradine : electrophysiological effects and safety.
    Savelieva I; Camm AJ
    Drug Saf; 2008; 31(2):95-107. PubMed ID: 18217787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of I(f) blockade: evidence and perspective.
    Borer JS
    Pharmacol Res; 2006 May; 53(5):440-5. PubMed ID: 16621590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate reduction during exercise-induced myocardial ischaemia and stunning.
    Monnet X; Colin P; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
    Eur Heart J; 2004 Apr; 25(7):579-86. PubMed ID: 15120055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS; Le Heuzey JY
    Am J Ther; 2008; 15(5):461-73. PubMed ID: 18806523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate reduction: a potential target for the treatment of myocardial ischaemia.
    Danchin N; Aly S
    Therapie; 2004; 59(5):511-5. PubMed ID: 15648303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
    Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selection and pharmacological characterisation of Procoralan, a selective inhibitor of the pacemaker If current].
    Vilaine JP
    Therapie; 2004; 59(5):495-505. PubMed ID: 15648301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.